JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Patients undergoing esophagectomy

Exclusion Criteria:

• Patients with more than mild pulmonary dysfunction

• Patients with any neuromuscular disease that might compromise diaphragm function

• Patients with abnormal liver or kidney function

• Patients taking any immunosuppressant medication (including prednisone) or antifungal medications

• History of tuberculosis

• Weight loss of >5% of body weight over previous 6 months

• Pregnancy